Sugi Predict

Sugi Predict / Compounds / SCHEMBL3105902

SCHEMBL3105902

SCHEMBL3105902

O=C(O)[C@@H](Cc1ccc(O)cc1)NI

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.56
▸ NAALAD2 Q9Y3Q0 1/20 0.56
▸ SLC7A5 Q01650 1/20 0.55
▸ MME P08473 6/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ ACE P12821 8/20 0.51
▸ CPA1 P15085 1/20 0.51
▸ ACE2 Q9BYF1 1/20 0.51
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55971 1.00 FOLH1 (0.56) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL55972 1.00 FOLH1 (0.56) FOLH1NAALAD2SLC7A5MMEMEN1
Methane SCHEMBL4610737 0.98 FOLH1 (0.55) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL188399 0.91 FOLH1 (0.49) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL188398 0.91 FOLH1 (0.49) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL28520123 0.89 FOLH1 (0.48) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL6037021 0.87 FOLH1 (0.46) FOLH1NAALAD2SLC7A5MMEMEN1
Carbamic Acid SCHEMBL7215414 0.87 SLC7A5 (0.46) FOLH1NAALAD2SLC7A5MMEMEN1
Sulfuric Acid SCHEMBL8910597 0.85 MEN1 (0.48) FOLH1NAALAD2SLC7A5MMEMEN1
Sulfuric Acid SCHEMBL8910593 0.85 MEN1 (0.48) FOLH1NAALAD2SLC7A5MMEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084413-B2 Urocortin-III and uses thereof RESEARCH DEVELOPMENT FOUNDATION (US) 2011-12-27 — — US claimed
US-7803774-B2 Modulators of β-amyloid peptide aggregation PRAECIS PHARMACEUTICALS, INC. (US) 2010-09-28 — — US claimed
US-20090156493-A1 UROCORTIN-III AND USES THEREOF VALE JR WYLIE W 2009-06-18 — — US claimed
EP-1870419-A2 Modulators of beta-amyloid peptide aggregation comprising d-amino acids Praecis Pharmaceuticals Incorporated (US) 2007-12-26 — — EP claimed
EP-1346041-B1 THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE PRAECIS PHARM INC (US) 2007-02-28 — — EP claimed
EP-1368051-A4 UROCORTIN-III AND USES THEREOF RES DEV FOUNDATION (US) 2005-11-02 — — EP claimed
US-20050137128-A1 Modulators of ß-amyloid peptide aggregation PRAECIS PHARMACEUTICALS, INC. (US) 2005-06-23 — — US claimed
US-6812210-B2 REGULATION OF NEUROENDOCRINE AND PARACRINE RESPONSES TO STRESS. RESEARCH DEVELOPMENT FOUNDATION 2004-11-02 — — US claimed
US-20040143095-A1 for treating high body temperature, appetite dysfunction, congestive heart failure, vascular disease, stress and anxiety; angiogenesis inhibitors; genetic engineering RESEARCH DEVELOPMENT FOUNDATION 2004-07-22 — — US claimed
US-6689752-B2 AMINO-TERMINAL MODIFYING GROUPS INCLUDE CYCLIC, HETEROCYCLIC, POLYCYCLIC AND BRANCHED ALKYLS, AND CARBOXY-TERMINAL MODIFYING GROUPS INCLUDE AN AMIDE, AN ALKYL AMIDE, AN ARYL AMIDE OR A HYDROXY; TREATING ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INCORPORATED 2004-02-10 — — US claimed
EP-1346041-A2 THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE Praecis Pharmaceuticals Incorporated (US) 2003-09-24 — — EP claimed
US-20030036507-A1 Regulation of neuroendocrine and paracrine responses to stress. NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-02-20 — — US claimed
WO-2002074326-A2 UROCORTIN-III AND USES THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2002-09-26 — — WO claimed
US-20020133001-A1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease PRAECIS PHARMACEUTICALS INC. 2002-09-19 — — US claimed
CN-1362967-A D-amino acid-containing regulator of beta-amyloid peptide aggregation PRAECIS PHARM INC (US) 2002-08-07 — — CN claimed
WO-2002042462-A2 THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE PRAECIS PHARMACEUTICALS INC. (US) 2002-05-30 — — WO claimed
WO-2000052048-A9 MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS PRAECIS PHARM INC (US) 2002-04-11 — — WO claimed
EP-1161449-A1 MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS Praecis Pharmaceuticals Incorporated (US) 2001-12-12 — — EP claimed
US-6303567-B1 FOR DIAGNOSIS AND THERAPY OF AMYLOIDOGENIC DISEASES SUCH AS ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INC . 2001-10-16 — — US claimed
WO-2000052048-A1 MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS PRAECIS PHARMACEUTICALS INCORPORATED (US) 2000-09-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020133001-A1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease APP, CLN6, PSEN1 FOLH1 564/4885NAALAD2 868/4885SLC7A5 2766/4885
US-20050137128-A1 Modulators of ß-amyloid peptide aggregation APP, IAPP, BACE1 FOLH1 1673/4885NAALAD2 172/4885SLC7A5 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.